Rheumatoid Arthritis

by Firestein, Gary; Panayi, Gabriel; Wollheim, Frank

• ISBN13: 9780198566304
• ISBN10: 0198566301
• Edition: 2nd
• Format: Hardcover
• Copyright: 2006-09-14
• Publisher: Oxford University Press

Summary

Rheumatoid arthritis (RA) is a chronic inflammatory disease, which affects 1% of the world's population. Patients with RA not only have a progressive and debilitating disease and severe functional impairment, but can also experience a reduced life expectancy due to frequent involvement of themajor organ systems. This new edition of Rheumatoid Arthritis charts the profound changes in research and patient management that have taken place over the last 5 years. Developments in molecular biology have dramatically increased insight into the inflammatory and destructive pathways of thiscomplex disease. Over half a million patients have been successfully treated with biologic therapy and advances in imaging techniques have allowed increasingly early detection of disease onset. Rheumatoid factor is no longer the unchallenged gold standard autoantibody but has competition from theanti-citrulline antibodies. Environmental factors influencing both susceptibility and progression have been sought, and smoking has emerged as a powerful factor. Steady progress in genetics is finally being made and one day it may be possible to predict RA before onset of symptomatic disease. It is against this backdrop of dynamic developments that the new edition of Rheumatoid Arthritis publishes.

Table of Contents

List of contributors	xiii
SECTION 1 ETIOLOGY
Genetics of rheumatoid arthritis	3	(12)
Peter K. Gregersen
Robert M. Plenge
Percio S. Gulko
Epidemiology and determinants of susceptibility	15	(16)
Jaime Calvo-Alen
Graciela S. Alarcon
Microbes in the pathogenesis of rheumatoid arthritis	31	(10)
Paavo Toivanen
Experimental models for RA	41	(14)
Rikard Holmdahl
SECTION 2 MECHANISMS OF INFLAMMATION
The role of macrophages in rheumatoid arthritis	55	(22)
Raimund W. Kinne
Bruno Stuhlmuller
Ernesta Palombo-Kinne
Gerd-R. Burmester
The role of T lymphocytes in rheumatoid arthritis	77	(18)
David A. Fox
The role of neutrophils in the pathogenesis of rheumatoid arthritis	95	(12)
W. Winn Chatham
Jeffrey C. Edberg
Robert P. Kimberly
The role of fibroblast-like synoviocytes in rheumatoid arthritis	107	(16)
Ulf Muller-Ladner
Steffen Gay
The roles of B cells in rheumatoid arthritis	123	(12)
Gregg J. Silverman
Innate immunity and immune complexes in rheumatoid arthritis	135	(22)
Peter A. Nigrovic
David M. Lee
Angiogenesis and cell trafficking	157	(16)
Christopher D. Buckley
Andrew Filer
Costantino Pitzalis
Cytokine networks	173	(20)
William P. Arend
Cem Gabay
Autoantibodies in rheumatoid arthritis: prevalence and clinical significance	193	(6)
Gunter Steiner
Josef S. Smolen
Mechanisms of fibroblast-mediated joint destruction	199	(14)
Thomas Pap
Renate Gay
Steffen Gay
Pain mechanisms in rheumatoid arthritis	213	(8)
Bruce L. Kidd
The stress system and the hypothalamic--pituitary--adrenal axis in rheumatoid arthritis	221	(8)
George P. Chrousos
Gregory A. Kaltsas
Examination of the synovium and synovial fluid	229	(16)
Paul-Peter Tak
SECTION 3 CLINICAL ASPECTS
Clinical aspects of rheumatoid arthritis	245	(14)
Nathan J Zvaifler
Imaging in rheumatoid arthritis	259	(26)
Mikkel Østergaard
Marcin Schudlarek
Bo Jannik Ejbjerg
Susceptibility, prognosis, and mortality	285	(16)
Marjatta Leirisalo-Repo
Biomarkers for cartilage and bone in rheumatoid arthritis	301	(16)
Tore Saxne
Bengt Mansson
Dick Heinegard
SECTION 4 DRUG THERAPY
NSAIDs and analgesics	317	(20)
Richard O. Day
Lynette M. March
Garry G. Graham
Kieran F. Scott
Kenneth M. Williams
Systemic and intra-articular glucocorticoids in rheumatoid arthritis	337	(18)
Johannes W. J. Bijlsma
Frank Buttgereit
Johannes W. G. Jacobs
The new frontiers in pathogenesis and treatment: methotrexate and leflunomide	355	(14)
Rolf Rau
Gold, antimalarials, sulfasalazine, and other DMARDs	369	(10)
Piet L. C. M. van Riel
Eric-Jan J. A. Kroot
Combination therapy with synthetic DMARDs in the treatment of rheumatoid arthritis	379	(8)
Antonios O. Aliprantis
Michael Weinblatt
Biologics in the treatment of rheumatoid arthritis	387	(14)
Zuhre Tutuncu
Arthur Kavanaugh
SECTION 5 NON-DRUG THERAPY
The impact of physiotherapy	401	(8)
Ulrich Moritz
Patient education	409	(4)
Ylva Lindroth
Occupational therapy and assistive products and technology	413	(8)
Ulla Nordenskiold
Psychological and social aspects	421	(12)
Tore Kristian Kvien
Liv Marit Smedstad
Non-drug management of chronic pain	433	(8)
Wolfgang Hamann
Health economics	441	(10)
Leigh F. Callahan
SECTION 6 SURGICAL THERAPY
Large joints and feet	451	(14)
Urban Rydholm
The hand	465	(10)
Christer Sollerman
The cervical spine	475	(12)
A. T. H. Casey
H. A. Crockard
SECTION 7 FRONTIERS OF THERAPY
Design of trials involving clinical end-points	487	(10)
Louise Pollard
Gabrielle Kingsley
David L. Scott
Clinical trials with imaging and biomarker end-points	497	(10)
Jane Freeston
Paul Emery
New biologics: cytokines	507	(12)
Jeffrey R. Curtis
Larry W. Moreland
New biologics: T and B modulators	519	(10)
Ernest Choy
Inhibition of proteolytic activity involved in cartilage breakdown	529	(12)
Tim E. Cawston
David A. Young
Signal transduction in rheumatoid arthritis	541	(10)
Di Chen
Edward M. Schwarz
Mesenchymal stem cells in arthritis	551	(10)
Frank P. Luyten
Index	561